Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis

References

• Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386:1565–1575. doi:10.1016/S0140-6736(15)00154-3
   PubMed Web of Science ®Google Scholar
• Marchall HU, Henriksson I, Lindenberg S, et al. Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort. Sci Rep. 2019;9:1–8.
   Web of Science ®Google Scholar
• Baldursdottir TR, Bergmann OM, Jonasson JG, et al. The epidemiology and natural history of primary biliary cirrhosis: a nationwide publication-based study. Eur J Gastroenterol Hepatol. 2012;24:824–830. doi:10.1097/MEG.0b013e328353753d
   PubMed Web of Science ®Google Scholar
• Murillo Perez CF, Goet JC, Lammers WJ, et al. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: a changing natural history. Hepatology. 2018;67:1920–1930. doi:10.1002/hep.29717
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145–172.
   PubMed Web of Science ®Google Scholar
• Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715–720. doi:10.1053/j.gastro.2005.12.029
   PubMed Web of Science ®Google Scholar
• Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871–877. doi:10.1002/hep.22428
   PubMed Web of Science ®Google Scholar
• Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis in patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136:1281–1287. doi:10.1053/j.gastro.2009.01.003
   PubMed Web of Science ®Google Scholar
• Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:2186–2194. doi:10.1038/ajg.2010.216
   PubMed Web of Science ®Google Scholar
• Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55:1361–1367. doi:10.1016/j.jhep.2011.02.031
   PubMed Web of Science ®Google Scholar
• Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147:1338–1349. doi:10.1053/j.gastro.2014.08.029
   PubMed Web of Science ®Google Scholar
• Murillo Perez CF, Harms MH, Lindor KD, et al. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol. 2020;115:1066–1074.
   Web of Science ®Google Scholar
• Harm MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid treatment and liver transplantation-free survival in patients with primary biliary cholangitis. J Hepatol. 2019;71:357–365. doi:10.1016/j.jhep.2019.04.001
   Web of Science ®Google Scholar
• Harm MH, Carbone M, Lammers WJ, et al. Clinical application of the Globe score and UK-PBC score in a real world trial cohort of patients with primary sclerosing cholangitis. Hepatol Commun. 2018;19:683–692.
   Google Scholar
• Selmi C, Bowlus CL, Gershwin ME, et al. Primary biliary cirrhosis. Lancet. 2011;377:1600–1609. doi:10.1016/S0140-6736(10)61965-4
   PubMed Web of Science ®Google Scholar
• Gerussi A, Lucà M, Cristoferi L, et al. New therapeutic targets in autoimmune cholangiopathies. Frontiers Med. 2020. doi:10.3389/fmed.2020.00117
   Web of Science ®Google Scholar
• Modica S, Petruzzelli M, Bellafante E, et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology. 2012;142:335–336. doi:10.1053/j.gastro.2011.10.028
   Web of Science ®Google Scholar
• Kowdley K, Luketic V, Chapman R, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology. 2018;67:1890–1902. doi:10.1002/hep.29569
   PubMed Web of Science ®Google Scholar
• Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–643. doi:10.1056/NEJMoa1509840
   PubMed Web of Science ®Google Scholar
• Trauner M, Nevens F, Shifmann ML, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: a 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol. 2019;4:445–453.
   PubMed Web of Science ®Google Scholar
• Pares A, Shiffman M, Vargas V, et al. Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. Liver Int. 2020;40:1121–1129. doi:10.1111/liv.14429
   Web of Science ®Google Scholar
• Bowlus CL, Pockros PJ, Kremer AE, et al. Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis. Clin Gastroenterol Hepatol. 2020;18:1170–1178. doi:10.1016/j.cgh.2019.09.050
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Floreani A, Trivedi PJ, et al. Long-term effect of obeticholic acid on transient elastography and AST to platelet ratio index in patients with PBC. Gut. 2017;66:A98–A99.
   Web of Science ®Google Scholar
• Roberts SB, Ismail M, Kanagalingam G, et al. Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis. Hepatol Commun. 2020;4:1332–1345. doi:10.1002/hep4.1518
   Web of Science ®Google Scholar
• Ghonem NS, Ananthanarayanan M, Soroka CJ, et al. Peroxisome proliferator-activated receptor alpha activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology. 2014;59:1030–1042. doi:10.1002/hep.26894
   PubMed Web of Science ®Google Scholar
• Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013;57:1931–1941. doi:10.1002/hep.26018
   PubMed Web of Science ®Google Scholar
• Corpechot C, Chazouilleres O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378:2171–2181. doi:10.1056/NEJMoa1714519
   PubMed Web of Science ®Google Scholar
• Summerfield JA, Elias E, Sherlock S. Effects of clofibrate in primary biliary cirrhosis: hypercholesterolemia and gallstones. Gastroenterology. 1975;69:998–1000. doi:10.1016/S0016-5085(19)32419-9
   PubMed Web of Science ®Google Scholar
• Reig A, Alvarez-Navascucs C, Vergara Gomez M, et al. Comparative effects of second-line therapy with obeticholic acid or fibrates in primary biliary cholangitis patients. J Hepatol. 2020;73:S460–S461 (FR126). doi:10.1016/S0168-8278(20)31404-5
   Web of Science ®Google Scholar
• Culver E, Hayden J, Thornburn D, et al. Obeticholic acid and bezafibrate in primary biliary cholangitis: a comparative evaluation of efficacy through real world clinical practice. Hepatology. 2019;suppl.1:770A.
   Google Scholar
• Sorel P-A, Lam L, Carrat F, et al. Additive beneficial effects of fibrates combined with obeticholic acid in the treatment of patients with primary biliary cholangitis and inadequate response to second-line therapy. Hepatology. 2019. late-breaking abstracts (LP6).
   Google Scholar
• De Vries E, Bolier R, Goet J, et al. Fibrates for itch in fibrosing cholangiopathies: a double blind, randomized, placebo, controlled trial. Gastroenterology. 2020. doi:10.1053/j.gastro.2020.10.001
   Web of Science ®Google Scholar
• Tully DC, Rucker PV, Chianelli D, et al. Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and non-alcoholic steatohepatitis (NASH). J Med Chem. 2017;60:9960–9973. doi:10.1021/acs.jmedchem.7b00907
   PubMed Web of Science ®Google Scholar
• Schramm C, Hirschfield G, Mason AL, et al. Early assessment of safety and efficacy of tropifexor, a potent non-bile acid FXR agonist, in patients with primary biliary cholangitis: an interim analysis of an ongoing phase 2 study. J Hepatol. 2018;suppl. 1(S 103):LB0–007.
   Google Scholar
• Trauner M, Gulamhusein A, Hameed B, et al. The non-steroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology. 2019;70:788–801. doi:10.1002/hep.30509
   PubMed Web of Science ®Google Scholar
• Schattenberg J, Pares A, Kowdley KV, et al. Elafibranor, a peroxisome proliferator-activated receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment. J Hepatol. 2019;suppl 1S:LBO–02.
   Google Scholar
• Jones D, Boudes PF, Swain MG, et al. Seladelpar (MBX-8025) a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid; a double blind, randomized, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017;2:716–726. doi:10.1016/S2468-1253(17)30246-7
   PubMed Web of Science ®Google Scholar
• Levy C, Bowlus C, Neff G, et al. Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study. J Hepatol. 2020;73:S464–S465 (FRI133). doi:10.1016/S0168-8278(20)31411-2
   Web of Science ®Google Scholar
• Russell DW. Fifty years of advances in the bile acid synthesis and metabolism. J Lipid Res. 2009;50:S120–S125. doi:10.1194/jlr.R800026-JLR200
   PubMed Web of Science ®Google Scholar
• May MJ, Wigg AJ, Leggett BA, et al. NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Commun. 2018;2:1–14.
   Web of Science ®Google Scholar
• Nishio T, Hu R, Koyama Y, et al. Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice. J Hepatol. 2019;71:573–585. doi:10.1016/j.jhep.2019.04.012
   PubMed Web of Science ®Google Scholar
• Dalekos GN, Invernizzi P, Nevens F, et al. Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: interim efficacy results of a phase 2 clinical trial. J Hepatol. 2019;70:e1–e2. doi:10.1016/S0618-8278(19)30002-7
   Web of Science ®Google Scholar
• Tsuda M, Moritoki Y, Lian ZX, et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and incomplete response to ursodeoxycholic acid. Hepatology. 2012;55:512–521.
   PubMed Web of Science ®Google Scholar
• Myers RP, Swain MG, Lee SS, et al. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol. 2013;108:933–941.
   PubMed Web of Science ®Google Scholar
• Khanna A, Jopson L, Howel D, et al. Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: a phase 2 randomized controlled trial. Hepatology. 2019;70:1646–1657. doi:10.1002/hep.30099
   PubMed Web of Science ®Google Scholar
• Chuang YH, Lian ZX, Cheng CM, et al. Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. J Autoimmun. 2005;25:126-–132. doi:10.1016/j.jaut.2005.08.009
   Web of Science ®Google Scholar
• Nishioji K, Okanoue T, Itoh Y, et al. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol. 2001;123:271–279. doi:10.1046/j.1365-2249.2001.01391.x
   PubMed Web of Science ®Google Scholar
• De Graaf KL, Lapeyre G, Guilhot F, et al. NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. Hepatol Commun. 2018;2:492–503. doi:10.1002/hep4.1170
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Gerschwin ME, Strauss R, et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study. Hepatology. 2016;64:189–199. doi:10.1002/hep.28359
   PubMed Web of Science ®Google Scholar
• Bowlus CL, Yang G-X, Liu CH, et al. Therapeutics trials of biologics in primary biliary cholangitis: an open-label study of abatacept and review of the literature. J Autoimmun. 2019;101:26–34. doi:10.1016/j.jaut.2019.04.005
   PubMed Web of Science ®Google Scholar
• Arsenijevic A, Harrell CR, Fellabaum C, Volarevic V. Mesenchimal stem cells as new therapeutic agents for the treatment of primary biliary cholangitis. Anal Cell Pathol. 2017;2017:7492836. doi:10.1155/2017/7492836
   Web of Science ®Google Scholar
• Alfaif M, Eom YW, Newsome PN, Baik SK. Mesenchymal stromal cell therapy for liver diseases. J Hepatol. 2018;68:1272–1285.
   Web of Science ®Google Scholar
• Wang L, Li J, Liu H, et al. A pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. J Gastroenterol Hepatol. 2013;28(suppl.1):85–92. doi:10.1111/jgh.12029
   PubMed Web of Science ®Google Scholar
• Wang L, Han Q, Chen H, et al. Allogenic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. Stem Cell Dev. 2014;23:2482–2489. doi:10.1089/scd.2013.0500
   PubMed Web of Science ®Google Scholar
• Mason A, Xu L, Guo L, et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet. 1998;35:1620–1624. doi:10.1016/S0140-6736(97)10290-2
   Web of Science ®Google Scholar
• Lytvyak E, Hosomani I, Montano-Loza AJ, et al. Randomized clinical trial: combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis. Can Liver J. 2019. doi:10.3138/canlivj.2018-0020
   Google Scholar
• Mayo MJ, Pockros PJ, Jones D, et al. A randomized, controlled, phase 2 study of maralixabat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun. 2019;3:365–381.
   Web of Science ®Google Scholar
• Hegade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK23330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389:1114–1123. doi:10.1016/S0140-6736(17)30319-7
   PubMed Web of Science ®Google Scholar
• Al-Dury S, Wahlström A, Wahlin S, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci Rep. 2018;8:6658. doi:10.1038/s41598-018-25214-0
   PubMed Web of Science ®Google Scholar
• Zenouzi R, Weiler-Normann C, Lohse AW. Is fatigue in primary biliary cirrhosis cured by transplantation? J Hepatol. 2013;59:418–419. doi:10.1016/j.jhep.2013.05.037
   Web of Science ®Google Scholar
• Hollingsworth K, Newton JL, Taylor R, et al. Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis. Clin Gastroenterol Hepatol. 2008;6:1041–1048. doi:10.1016/j.cgh.2008.04.013
   PubMed Web of Science ®Google Scholar
• Jones DEJ, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther. 2007;25:471–476. doi:10.1111/j.1365-2036.2006.03223.x
   PubMed Web of Science ®Google Scholar
• Millar B, Richardson C, McKay K, et al. Obeticholic acid therapy improves cognitive decline in cholestatic liver disease. J Hepatol. 2017;66:FR396. doi:10.1016/S0168-8278(17)31070-X
   Web of Science ®Google Scholar